Disclosure of Voting results of E G M (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Jagsonpal Pharmaceuticals Ltd has informed BSE regarding the details of Voting results at the Extra Ordinary General Meeting (AGM) of the Company held on April 12, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Outcome of EGM
Jagsonpal Pharmaceuticals Ltd has informed BSE that the Extra Ordinary General Meeting (EGM) of the Company was held on April 12, 2016. Outcome of Board Meeting
Jagsonpal Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on February 17, 2016."The meeting was convened and being in order it was unanimously decided by the Board of Directors proceed with for postal Ballot u/s 110 and e-voting 108 as the matter is under section 180 (1) (a) and 188 of Companies Act, 2013 and to convene Extra Ordinary General Meeting ("EGM") if necessary.... Board Meeting on Feb 17, 2016
Jagsonpal Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 17, 2016, inter alia, to consider and approve the notice and date for Extra Ordinary General Meeting of the Company. Financial Results, Limited Review Report for December 31, 2015
Jagsonpal Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20152. Standalone Limited Review for the period ended December 31, 2015 Updates on Outcome of Board Meeting
Jagsonpal Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 12, 2016, inter alia, has transacted the following:Managing Director informed the Board that pursuant to board meeting dated January 25, 2016, he has entered into an agreement with a party relating to disposing of fixed assets of Pantnagar plant by way of sale on February 12, 2016.... Outcome of Board Meeting
Jagsonpal Pharmaceuticals Ltd has submitted to BSE a copy of Proceedings of the Meeting of the Board of Directors of the Company held on January 25, 2016"Mr. Bharat Sinh, Independent Director, explained that there are number of changes under Company Act 2013, SEBI (LODR 2015) and other laws which require compliances more often as compared to Companies Act, 1956, SEBI and other laws. SEBI has modified new Listing Agreements and all the Listed... Board Meeting on Jan 25, 2016
Jagsonpal Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on January 25, 2016, inter alia, to Consider the following:1. To authorize Managing Director and/or Company Secretary to sign, execute and file the new Listing Agreement, pursuant to the amendments, with NSE & BSE and to comply other provisions in relation to the applicable provisions of Companies Act, 2013 as amended upto date.... Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Jagsonpal Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Authorised KMPs to determine materiality of events/information
Jagsonpal Pharmaceuticals Ltd has informed BSE regarding "Authorised Key Managerial Personnel to determine materiality of events/information".